)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Pila Pharma
Pila Pharma (PILA) investor relations material
Pila Pharma H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary27 Aug, 2026
Executive summary
Regulatory approval received for a 12-week clinical trial (PP-CT04) of XEN-D0501 in obesity, marking a significant step in clinical development.
Focus remains on advancing TRPV1 antagonist for obesity, diabetes, and rare disease erythromelalgia.
The company operates virtually, relying on consultants and CROs for R&D activities.
Financial highlights
Operating income was TSEK 0, down from TSEK 851 in the same period last year.
EBIT for the first half was TSEK -3,850, an improvement from TSEK -4,092 year-over-year.
Net result for the period was TSEK -3,867, compared to TSEK -4,102 year-over-year.
Cash flow from operating activities was TSEK -17,974, including a TSEK 13,195 transfer to the Danish subsidiary.
Cash at period end: TSEK 3,257 (parent) and TSEK 10,126 (Danish subsidiary).
Outlook and guidance
The new clinical trial aims to establish safety and efficacy at higher doses and longer durations, potentially enabling further studies in obesity and related diseases.
No explicit financial or revenue guidance provided for the remainder of the year.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Pila Pharma
- Strategic refocus, strong financing, and clinical trial preparations mark 2025.PILA
H2 2025 - Strong rights issue funding supports new obesity drug focus, with preclinical results due by early 2026.PILAH1 2025
- Oral TRPV1 drug for diabetes and obesity advances, with new funding and pivotal studies ahead.PILAInvestor Update
- Preparing a dose escalation trial for diabetes/obesity, with expanded pipeline and active investor outreach.PILAInvestor Update
- SEK 10M raised, Phase 2a trial prep, new CEO, improved results, and rising investor interest.PILAH1 2024
- R&D and funding ramped up for a unique obesity drug, with stable liquidity and net loss.PILAH2 2024
Next Pila Pharma earnings date
H2 202625 Feb, 2027
Pila Pharma
Next Pila Pharma earnings date
H2 202625 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
PILA PHARMA AB (publ) is a clinical stage pharmaceutical company developing XEN-D0501, a TRPV1 antagonist targeting the prevention and treatment of type 2 diabetes. The product candidate has completed two phase 2a clinical trials. Once it completes its ongoing phase 2b trial, PILA PHARMA AB (publ) is planning to initiate pivotal phase 3 study.